Takeda could acquire next-generation immunotherapies ... The company has had success with Ninlaro in multiple myeloma and its antibody-drug conjugate Adcetris in blood cancers including classical ...
Takeda is discontinuing a trial of its drug Ninlaro in systemic light-chain AL amyloidosis after it did not meet the first of two primary endpoints. The phase 3 TOURMALINE-AL1 trial was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback